Cardiff Oncology
CRDF
48 hedge funds and large institutions have $4.25M invested in Cardiff Oncology in 2017 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 23 reducing their positions, and 22 closing their positions.
0.1% less ownership
Funds ownership: 0.25% → 0.15% (-0.1%)
23% less funds holding
Funds holding: 62 → 48 (-14)
34% less capital invested
Capital invested by funds: $6.47M → $4.25M (-$2.22M)
59% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 22
70% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$228K |
| 2 |
Millennium Management
New York
|
+$220K |
| 3 |
ECM
Element Capital Management
New York
|
+$118K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
+$107K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$76K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.13M |
| 2 |
State Street
Boston,
Massachusetts
|
-$367K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$262K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$233K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$178K |
CRDF Hedge Fund Activity: Q2 2017 in Review
48 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q2 2017, worth a combined $4.25M — down 34% from $6.47M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of CRDF and 9 opened new positions — a net loss of 13 holders — while 23 trimmed existing stakes and 7 added.
The largest buyer was Goldman Sachs, adding an estimated $228K. The largest seller was BlackRock, cutting an estimated $1.13M.
- 48 institutional investors held Cardiff Oncology (CRDF) as of Q2 2017, down from 62 in Q1 2017.
- Funds reported $4.25M of Cardiff Oncology stock for Q2 2017, down 34% quarter-over-quarter.
- 9 funds opened new Cardiff Oncology positions in Q2 2017 and 22 closed out, a net change of -13 holders.
- The largest Cardiff Oncology buyer in Q2 2017 was Goldman Sachs, an estimated $228K added.
- The largest Cardiff Oncology seller in Q2 2017 was BlackRock, an estimated $1.13M sold.
Based on aggregated 13F filings for Q2 2017.